EOHILIA™ (budesonide oral suspension) is an FDA approved 12-week oral treatment for EoE in people 11 years and older. It has not been shown to be safe and effective for longer than 12 weeks. Website …

Patient access info for EOHILIA™ (budesonide oral suspension) treatment. Website for U.S. Healthcare Professionals. See Important Safety Information and Full Prescribing Information.

UnitedHealthcare Pharmacy Clinical Pharmacy Programs ... Background: Eohilia (budesonide oral suspension)* is a corticosteroid indicated for 12 weeks of treatment in adult and pediatric patients 11 …

Mar 17, 2025 · Historic EoE Treatments Eohilia is the first FDA-approved medication specifically designed for the treatment of EoE. It is an oral suspension of budesonide, a corticosteroid that …

Sep 1, 2025 · Overview Eohilia (budesonide) oral suspension is a corticosteroid indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis …

What is EOHILIA? EOHILIA is a prescription oral corticosteroid medicine used for 12 weeks of treatment of Eosinophilic Esophagitis (EoE), in people 11 years and older.

February 12, 2024 - Takeda announced the FDA approval of Eohilia (budesonide), for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE).

Get started on EOHILIA™ (budesonide oral suspension). Talk to your doctor, manage costs with support programs, and find specialists. See Important Safety Information and Prescribing Information.

Oct 15, 2024 · Eohilia (budesonide) is a corticosteroid that's FDA approved to treat eosinophilic esophagitis (EoE) in adults and children. The dosage is typically a packet taken by mouth twice daily …

The EOHILIA Patient Support and Copay Program The EOHILIA Patient Support and Copay Program is designed to help guide you along your EoE treatment journey. Eligible commercial patients may …